| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 1.02 [0.95, 1.10] | | < 1 | | 0% | 12 studies (12/-) | 27.2 % | some concern | low | moderate | crucial | - |
| death or transfer to ICU | 1.09 [0.99, 1.20] | | < 1 | | 0% | 1 study (1/-) | 4.0 % | NA | not evaluable | | crucial | - |
| deaths | 0.99 [0.94, 1.04] | | < 1 | | 0% | 34 studies (34/-) | 65.2 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.98 [0.89, 1.07] | | < 1 | | 30% | 10 studies (10/-) | 67.0 % | some concern | low | moderate | crucial | - |
| clinical deterioration | 0.78 [0.56, 1.10] | | < 1 | | 14% | 7 studies (7/-) | 92.2 % | some concern | not evaluable | moderate | important | - |
| clinical improvement | 1.18 [0.94, 1.48] | | > 1 | | 62% | 13 studies (13/-) | 92.4 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.06 [0.87, 1.31] | | > 1 | | 54% | 15 studies (15/-) | 72.2 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.31 [0.97, 1.76] | | > 1 | | 66% | 6 studies (6/-) | 96.0 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.30 [1.04, 1.63] | | > 1 | | 43% | 9 studies (9/-) | 98.9 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.26 [1.06, 1.51] | | > 1 | | 53% | 7 studies (7/-) | 99.5 % | some concern | not evaluable | moderate | important | - |
| death or ventilation | 1.03 [0.93, 1.14] | | < 1 | | 63% | 4 studies (4/-) | 30.4 % | some concern | not evaluable | moderate | important | - |
| hospital discharge | 0.96 [0.85, 1.08] | | > 1 | | 69% | 7 studies (7/-) | 24.5 % | some concern | not evaluable | moderate | important | - |
| mechanical ventilation | 0.90 [0.73, 1.13] | | < 1 | | 38% | 15 studies (15/-) | 81.6 % | some concern | low | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.09 [0.01, 0.78] | | > 1 | | 0% | 2 studies (2/-) | 1.5 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.71 [1.11, 2.65] | | > 1 | | 49% | 8 studies (8/-) | 99.2 % | some concern | not evaluable | moderate | important | - |
| viral clearance (time to event analysis only) | 1.32 [1.03, 1.69] | | > 1 | | 0% | 2 studies (2/-) | 98.6 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 0.99 [0.93, 1.06] | | > 1 | | 0% | 8 studies (8/-) | 40.5 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 7 | 1.20 [0.77, 1.89] | | > 1 | | 32% | 6 studies (6/-) | 78.8 % | some concern | not evaluable | moderate | important | - |
| ICU admission | 0.91 [0.72, 1.15] | | < 1 | | 3% | 8 studies (8/-) | 77.8 % | some concern | not evaluable | moderate | non important | - |
| recovery | 1.18 [1.02, 1.36] | | > 1 | | 0% | 4 studies (4/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 0.96 [0.75, 1.24] | | < 1 | | 0% | 16 studies (16/-) | 61.6 % | some concern | low | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.56 [1.21, 2.01] | | < 1 | | 51% | 11 studies (11/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.43 [1.00, 2.05] | | < 1 | | 0% | 2 studies (2/-) | 2.5 % | some concern | not evaluable | moderate | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
